AI-Designed Cancer Vaccine for Advanced Solid Tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new mRNA vaccine designed by artificial intelligence to treat advanced cancers that have stopped responding to standard chemotherapy. The vaccine is personalized to each patient's tumor and aims to help the immune system fight remaining cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–70 years
- Advanced cancer (solid tumor) that has progressed despite at least two lines of prior treatment
- Good overall health and ability to care for yourself (ECOG score 0–1)
- At least 3 months expected survival
- Normal blood counts, liver, kidney, and heart function within the past 2 weeks
- At least 4 weeks since last chemotherapy, radiation, or surgery (6 weeks for certain chemotherapy drugs)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized cancer vaccine made from synthetic long peptide “neoantigens,” aiming to be safe and help the immune system fight certain solid tumors. It may fit people with pancreatic cancer after starting first-line chemotherapy, and some other solid tumors with limited options.
This trial tests a personalized cancer vaccine made from your own immune cells to help your body fight the tumor. It is for people with solid tumors that have not responded to other treatments.
This trial tests a personalized neoantigen vaccine given along with an anti-PD1 drug (pembrolizumab) and chemotherapy after surgery for pancreatic cancer. The goal is to see if this combination can help prevent the cancer from coming back.
This early-stage trial tests a new mRNA-based drug designed to help your immune system fight advanced cancers that haven't responded to standard treatments. The study measures safety, tolerability, and whether it can slow or shrink your tumor.
This trial tests a personalized vaccine made from “neoantigens” (tumor-specific targets) to help your immune system fight advanced, inoperable solid tumors. It may be an option if standard treatment didn’t work or you stopped it and your health is strong enough for trial treatment.
This trial tests a personalized mRNA vaccine made from your own tumor's unique markers (neoantigens). It is for people with advanced pancreatic cancer that has spread or come back, and who have had limited or no prior chemotherapy. The goal is to see if this vaccine can help the immune system fight the cancer.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.